Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29567529 | 0.97 | ALDH1A1 (0.31) | ALDH1A1TDP1LMNA | |
| Hydrochloric Acid SCHEMBL30896140 | 0.97 | ALDH1A1 (0.31) | ALDH1A1TDP1LMNA | |
| SCHEMBL25356001 | 0.83 | — | — | |
| SCHEMBL2944202 | 0.83 | — | — | |
| SCHEMBL24587176 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL18172348 | 0.81 | LMNA (0.36) | ALDH1A1LMNAPOLB | |
| Hydrochloric Acid SCHEMBL20166384 | 0.81 | LMNA (0.36) | ALDH1A1LMNAPOLB | |
| Hydrochloric Acid SCHEMBL20167235 | 0.81 | LMNA (0.36) | ALDH1A1LMNAPOLB | |
| Hydrochloric Acid SCHEMBL20167404 | 0.79 | LMNA (0.35) | ALDH1A1LMNAPOLB | |
| Hydrochloric Acid SCHEMBL20167233 | 0.79 | LMNA (0.35) | ALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626881-A1 | PREPARATION OF FUSED AZOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4612153-A1 | PREPARATION OF PYRAZOLOPYRIDINE AND TRIAZOLOPYRIDINE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024118858-A1 | PREPARATION OF FUSED AZOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024097576-A1 | PREPARATION OF PYRAZOLOPYRIDINE AND TRIAZOLOPYRIDINE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-05-10 | — | — | WO | disclosed |
| US-11976061-B2 | Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | Merck Sharp & Dohme, LLC (US) | 2024-05-07 | — | — | US | disclosed |
| US-11976061-B2 | Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | Merck Sharp & Dohme, LLC (US) | 2024-05-07 | — | — | US | disclosed |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-11-16 | — | — | US | disclosed |
| CN-116685577-A | Preparation of benzimidazolone derivatives as novel diacylglycerol O-acyltransferase 2 inhibitors | 默沙东有限责任公司 | 2023-09-01 | — | — | CN | disclosed |
| EP-4225735-A1 | PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4225739-A1 | PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-116457346-A | Preparation of indolone derivatives as novel diacylglycerol O-acyltransferase 2 inhibitors | 默沙东有限责任公司 | 2023-07-18 | — | — | CN | disclosed |
| WO-2022076495-A1 | PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076496-A1 | PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2010005783-A1 | PYRROLIDINYL AND PIPERIDINYL COMPOUNDS USEFUL AS NHE-1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | WO | disclosed |
| US-7456194-B2 | Imidazo-fused oxazolo [4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | ALDH1A1 3594/4885TDP1 1675/4885LMNA 3180/4885 |
| US-11976061-B2 | Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | DGAT2, DGAT1, ACAT2 | ALDH1A1 869/4885TDP1 2873/4885LMNA 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.